Ascendis Pharma A/S (ASND) Stock Price & How to Invest
Last updated November 2026
Short answer
ASND is Ascendis Pharma A/S, a Danish biopharmaceutical company listed on Nasdaq as American Depositary Shares, which has turned its TransCon prodrug chemistry into three approved rare-disease medicines and roughly EUR 1.05 billion of trailing revenue. It is no longer a story stock waiting on a first approval, it is a commercial-stage rare-disease company whose valuation now rests on how fast YORVIPATH and the newly approved YUVIWEL scale. As of October 16, 2026 the shares closed at $226.18, up about 6% year to date, the same day TransCon CNP received a positive CHMP opinion in Europe.
ASND stock price
As of 2026-11-16, Ascendis Pharma A/S (ASND) last closed at $271.73, up 25.5% over the past year. Over the past 52 weeks it has traded between $196.63 and $277.18.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Ascendis Pharma A/S's investor relations page. Walnut is informational, not investment advice.
ASND key stats
At $271.73 on November 16, 2026, Ascendis Pharma A/S (ASND) has a market cap of $17.9B and a P/E of 20.8 on trailing earnings (27.2 on forward earnings).
- Market cap
- $17.9B
- P/E (trailing)
- 20.8
- P/E (forward)
- 27.2
- EPS (trailing 12 months)
- $13.05
- Price to book
- 11.1
Market cap, P/E and yield are measured at the $271.73 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Ascendis Pharma A/S (ASND)?
The last two weeks for Ascendis Pharma A/S, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- ASND closed at $271.73 on November 16, 2026, up 4.6% over the past five trading days (from $259.85).
- On November 12, 2026, Ascendis Pharma A/S filed a current report (6-K) with the SEC. Read the 6-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Ascendis Pharma A/S (ASND) do?
Ascendis Pharma A/S trades on Nasdaq under ASND as American Depositary Shares, each representing one ordinary share of a company headquartered in Hellerup, Denmark. The business is built on TransCon, a prodrug technology that attaches a known parent drug to a carrier through a linker that releases the active molecule slowly and predictably, which lets Ascendis convert daily injections into weekly or monthly dosing. Three products are approved and marketed: SKYTROFA (lonapegsomatropin) for pediatric growth hormone deficiency, YORVIPATH (palopegteriparatide) for adult hypoparathyroidism, and YUVIWEL (navepegritide, developed as TransCon CNP), which received accelerated FDA approval with orphan exclusivity in May 2026 for pediatric achondroplasia. On October 16, 2026 the European Medicines Agency's CHMP issued a positive opinion recommending TransCon CNP for children with achondroplasia, the step that normally precedes a European Commission decision. Trailing twelve month revenue is roughly EUR 1.05 billion, with gross margin near 91 percent.
The growth is concentrated in one product. In the first quarter of 2026 Ascendis reported total revenue of roughly EUR 247 million, of which YORVIPATH contributed roughly EUR 197 million and SKYTROFA roughly EUR 44 million. Second-quarter revenue rose to roughly EUR 340 million, up about 115 percent from a year earlier, and EPS of 0.90 beat the 0.77 consensus. Reported net profit of roughly EUR 629 million in the first quarter was dominated by a one-time recognition of a roughly EUR 679 million deferred tax asset, and management pointed to non-IFRS net profit of roughly EUR 18 million as the closer read on underlying operations that quarter. That distinction matters when reading the headline trailing price to earnings ratio near 17, because much of the trailing roughly EUR 742 million of net income is an accounting event rather than cash; trailing free cash flow is only about EUR 13 million.
September 2026 brought two capital decisions. Ascendis and Novo Nordisk ended their collaboration, returning to Ascendis the rights to TransCon programs in metabolic and cardiovascular disease, including once-monthly TransCon Semaglutide for obesity and type 2 diabetes, with neither party carrying continuing financial obligations. Ascendis also announced a planned $400 million share repurchase program. The stock, worth about $14.9 billion, is up about 6% for 2026 and 9% over a year, but down about 11% over three months and well below its 52-week high of $282.15.
What's driving Ascendis Pharma A/S (ASND)?
1. YORVIPATH is carrying the model
Hypoparathyroidism had no chronic hormone-replacement standard for years after Takeda withdrew Natpara, leaving a diagnosed population managed on calcium and active vitamin D. YORVIPATH stepped into that vacuum and grew to roughly EUR 197 million in the first quarter of 2026, and total company revenue reached roughly EUR 340 million in the second. Analysts expect about EUR 1.37 billion of 2026 revenue and about EUR 2.02 billion in 2027. The variables to watch are patient adds, persistence on therapy, and how much of the addressable population is reached before growth normalizes.
2. YUVIWEL opens a second large launch
Accelerated approval in May 2026 gave Ascendis a competitive entry in pediatric achondroplasia, a market BioMarin established with Voxzogo. The company reported more than 170 unique patient enrollments by June 30, 2026, with reimbursement approval above 65 percent, which is the early metric that matters because payer coverage gates conversion from enrollment to revenue. The October 2026 positive CHMP opinion opens the path to Europe. Two-year ApproaCH data on lower-extremity alignment is the clinical argument being used to differentiate, and Ascendis is presenting further achondroplasia and hypoparathyroidism data at ASBMR 2026.
3. Platform reuse lowers the cost of the next program
TransCon is applied to parent molecules whose biology is already validated, which shifts the risk profile toward formulation and dosing rather than target discovery. That has produced a pipeline reaching beyond endocrinology and rare disease into oncology candidates, and since September 2026 into metabolic disease on its own account: after the Novo Nordisk collaboration ended, Ascendis regained TransCon Semaglutide, a once-monthly prodrug candidate for obesity and type 2 diabetes, and said it plans multiple programs across rare and large indications. No development budget or clinical start date had been disclosed for the monthly candidate.
4. The path to sustained operating profitability
Gross margin near 91 percent is excellent, but commercial buildout across three simultaneous launches and continued research spending absorb much of the gross profit, and trailing free cash flow is only about EUR 13 million even though operating cash flow is about EUR 350 million. Yahoo's latest balance sheet shows about EUR 812 million of cash against about EUR 450 million of debt, a stronger position than earlier in the year, and the planned $400 million buyback signals management's confidence in cash generation. Analysts expect EPS to fall in 2027 from the tax-boosted 2026 level, so the timing of durable operating profit remains the key number.
What are the risks to Ascendis Pharma A/S (ASND)?
Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. AstraZeneca's eneboparatide and other parathyroid hormone programs target the same indication, while BioMarin's Voxzogo is entrenched in achondroplasia and a long-acting successor is in development, and oral FGFR3 approaches could reframe the category entirely; in October 2026 the FDA granted priority review to BridgeBio's achondroplasia filing. YUVIWEL was cleared under accelerated approval, which carries confirmatory evidence obligations that can constrain or withdraw a label. Taking back TransCon Semaglutide moves the cost and risk of an obesity program, a field crowded with the largest drugmakers, onto Ascendis alone. UBS cut its price target to $269 from $307 in October 2026. Ascendis is a foreign private issuer that reports in euros and files Form 20-F, so currency translation and a lighter interim disclosure cadence than a domestic filer both apply. On the legal side, Ascendis is an appellant in patent litigation against BioMarin at the Federal Circuit (No. 26-1026), and plaintiffs' firms publicized securities class action investigation notices in 2023 following the FDA deficiency letter on TransCon PTH, though those solicitations are not the same as a filed complaint and no active securities-fraud class action was identified as of August 2026.
What is the Ascendis Pharma A/S (ASND) forecast?
21 analysts publish price targets on ASND, averaging $304.78 as of November 2026, or +12.2% against the $271.73 share price on November 16, 2026. The published targets run from $261.11 to $342.35, a narrow spread, and the ratings split 20 buy, 1 hold, 0 sell. Over the last six months there has been 1 raise and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full ASND forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is ASND a buy or a sell?
We give no verdict on Ascendis Pharma A/S. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. YORVIPATH is carrying the model. Hypoparathyroidism had no chronic hormone-replacement standard for years after Takeda withdrew Natpara, leaving a diagnosed population managed on calcium and active vitamin D. The most optimistic published target, $342.35, assumes this works close to its best case.
The case against. Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. The most pessimistic target, $261.11, is roughly what ASND is worth if this bites instead.
Read the full bull and bear case on ASND, including what would have to change to break either one. Walnut is not an investment adviser.
Has Ascendis Pharma A/S (ASND) split its stock?
No. Ascendis Pharma A/S (ASND) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Ascendis Pharma A/S (ASND) valued?
Market cap, P/E and dividend yield at today's price are in the ASND key stats above. The business figures below come from Ascendis Pharma A/S's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~EUR 1.05 billion; Q2 2026 ~EUR 340 million, up ~115%
- Q2 2026 EPS: 0.90 vs ~0.77 consensus
- Profitability: Gross margin ~91%; TTM net income ~EUR 742 million, inflated by a ~EUR 679 million one-time tax asset
- Balance sheet: Cash ~EUR 812 million against debt ~EUR 450 million; $400 million buyback planned
- Cash flow (TTM): Operating cash flow ~EUR 350 million; free cash flow ~EUR 13 million
As of October 2026: The trailing earnings multiple is the number most likely to mislead here, because trailing net income is driven largely by the roughly EUR 679 million deferred tax asset recognized in the first quarter of 2026, not by operations. Price to sales near 14x and forward price to earnings near 21x are the cleaner framing, and both price in continued rapid growth; consensus calls for third-quarter revenue of about EUR 367 million. The mean analyst target of about $307 across 21 analysts sits well above the $226 share price.
Who competes with Ascendis Pharma A/S (ASND)?
Rare endocrine and hypoparathyroidism therapies
YORVIPATH competes for a market that opened when Takeda's Natpara was withdrawn. AstraZeneca, through its Amolyt acquisition, is advancing eneboparatide for the same indication, and conventional management with calcium and active vitamin D remains the incumbent standard of care that Ascendis has to displace patient by patient.
Achondroplasia and growth disorders
YUVIWEL enters a category BioMarin created with Voxzogo and where BioMarin is developing a longer-acting successor, while Tyra Biosciences and others pursue oral FGFR3 inhibition that would change dosing expectations. In growth hormone deficiency, SKYTROFA competes with Novo Nordisk's Norditropin and Sogroya, Pfizer and Opko's Ngenla, and the entrenched daily somatropin products.
Long-acting drug delivery platforms
The TransCon technology competes conceptually with other half-life extension approaches, including PEGylation, Fc fusion and XTEN-style polypeptide extension used by companies such as Amunix and Halozyme licensees. These are less direct product rivals and more competing answers to the same question of how to turn a daily injection into a weekly or monthly one.
What stocks are similar to Ascendis Pharma A/S (ASND)?
Other names that sit close to ASND: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Ascendis Pharma A/S (ASND)
There are three common ways to get ASND exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ASND sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where ASND fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Ascendis Pharma A/S (ASND)
Ascendis has crossed from clinical promise to real product revenue, with second-quarter 2026 sales roughly doubling year over year, and the open question is whether launch economics can grow into a market capitalization of roughly $14.9 billion while the company also takes back its obesity program from Novo Nordisk.
More on Ascendis Pharma A/S (ASND)
Whether ASND is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ASND a buy or a sell?, and where the stock could go from here in the ASND stock forecast.
For income investors, whether ASND pays a dividend and how the payout looks is covered in does ASND pay a dividend? And to weigh ASND against a peer, read the full side-by-side comparisons: ASND vs AZN and ASND vs NVO.
Wondering how ASND fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Ascendis Pharma A/S
Ask Walnut's AI anything about ASND and see how it fits what you own.
FAQ
What company is ASND stock?
+
ASND is the Nasdaq ticker for Ascendis Pharma A/S, a biopharmaceutical company headquartered in Hellerup, Denmark. US investors hold American Depositary Shares rather than the Danish ordinary shares directly. The company uses its TransCon prodrug technology to develop long-acting versions of established therapies for rare endocrine and growth conditions.
What products does Ascendis Pharma sell?
+
Three approved products generate revenue. SKYTROFA (lonapegsomatropin) treats pediatric growth hormone deficiency, YORVIPATH (palopegteriparatide) treats adult hypoparathyroidism, and YUVIWEL (navepegritide) received accelerated FDA approval in May 2026 for pediatric achondroplasia and a positive CHMP opinion in Europe in October 2026. YORVIPATH is by far the largest contributor at roughly EUR 197 million in the first quarter of 2026.
Is Ascendis Pharma profitable?
+
It depends on which line you read. Trailing reported net income of roughly EUR 742 million is dominated by a one-time deferred tax asset recognition of roughly EUR 679 million in the first quarter of 2026. The company pointed to non-IFRS net profit of roughly EUR 18 million that quarter as the underlying figure, second-quarter EPS of 0.90 beat consensus, and trailing operating cash flow is about EUR 350 million, though free cash flow is close to breakeven.
Why is ASND stock up so much?
+
Revenue has more than doubled year over year as YORVIPATH scaled into a hypoparathyroidism market with no chronic hormone-replacement incumbent. The May 2026 accelerated approval of YUVIWEL for pediatric achondroplasia added a second large launch, and the company was added to the Russell 1000, Russell 3000 and Russell Midcap indexes in June 2026. The run has cooled since: as of October 16, 2026 the stock is up about 6% for the year but down about 11% over three months.
What is TransCon technology?
+
TransCon is a prodrug approach that links an unmodified parent drug to a carrier through a linker engineered to release the active molecule at a predictable rate. Because the released molecule is the same one already validated in clinical use, the primary risk shifts toward release kinetics and dosing rather than novel target biology. It is what allows weekly or monthly dosing where the original required daily injection.
Who competes with Ascendis Pharma?
+
In achondroplasia the main rival is BioMarin, whose Voxzogo established the category and which is developing a longer-acting successor. In hypoparathyroidism, AstraZeneca is advancing eneboparatide following its Amolyt acquisition. In growth hormone deficiency, SKYTROFA competes with Novo Nordisk's Norditropin and Sogroya and with Pfizer and Opko's Ngenla.
Is Ascendis Pharma facing any lawsuits?
+
Ascendis is an appellant in patent litigation against BioMarin at the Federal Circuit (No. 26-1026), which relates to the achondroplasia space. Plaintiffs' firms published securities class action investigation notices in 2023 after the FDA issued a deficiency letter on the TransCon PTH application, but those were solicitations rather than filed complaints, and no active securities-fraud class action was identified as of August 2026.
When does Ascendis Pharma report earnings?
+
Ascendis reported first quarter 2026 results on May 7, 2026 and second quarter results on August 13, 2026. Third-quarter results are expected in the fall, with consensus revenue of about EUR 367 million. As a foreign private issuer it files an annual report on Form 20-F rather than a 10-K, and reports interim results on Form 6-K, which is a lighter disclosure cadence than a domestic filer.
How did Ascendis Pharma do in its latest quarter?
+
In the second quarter of 2026 revenue rose to roughly EUR 340 million, about 115 percent higher than a year earlier and up from roughly EUR 247 million in the first quarter, driven mainly by YORVIPATH. EPS of 0.90 beat the 0.77 consensus. By June 30 YUVIWEL had more than 170 unique patient enrollments.
Why did Ascendis end its collaboration with Novo Nordisk?
+
Ascendis announced on September 14, 2026 that its collaboration with Novo Nordisk was terminated and that rights to TransCon programs in metabolic and cardiovascular disease, including once-monthly TransCon Semaglutide for obesity and type 2 diabetes, revert to Ascendis, with no continuing financial obligations on either side. Ascendis said it plans to start multiple programs, but has not disclosed a budget or clinical start date.
How has ASND stock performed in 2026?
+
ASND closed at $226.18 on October 16, 2026, up about 6% year to date and about 9% over the past year, within a 52-week range of $186.05 to $282.15. It is down about 11% over three months, and in September the company announced a planned $400 million share repurchase program.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Ascendis Pharma A/S's investor relations page or your broker before making investment decisions.